Novo Nordisk Makes $5.2bn Bet on U.S. Biotech Akero to Bolster Liver Disease Pipeline and Reignite Growth

Novo Nordisk has announced plans to acquire U.S.-based Akero Therapeutics in a deal worth up to $5.2 billion, marking the Danish drugmaker’s first major move under its new CEO Mike Doustdar. The acquisition gives Novo access to efruxifermin, a late-stage experimental drug that targets metabolic dysfunction-associated steatohepatitis (MASH) — a severe liver condition increasingly linked

Read More